Immunotherapy Versus Chemotherapy Efficacy in Promoting Survival of NSCLC
Faculty Sponsor
Jana Stedman
College
Nursing
Department/Program
Physician Assistant
Presentation Type
Poster Presentation
Symposium Date
Spring 7-24-2024
Abstract
Objectives: To determine the first line therapy for treating non-small cell lung cancer (NSCLC), based on the efficacy of immunotherapy plus chemotherapy in comparison to chemotherapy alone using overall survival and progression-free survival data. Methods: A literature review was performed by searching on Valpo Summon. The randomized controlled trials (RCTs) compared immunotherapy plus chemotherapy to chemotherapy alone in NSCLC with available primary endpoints of progression-free survival (PFS) and overall survival (OS). In addition, randomized controlled trials that compared immunotherapy as a monotherapy to chemotherapy monotherapy in NSCLC with progression-free survival and overall survival as secondary endpoints. Results: Progression-free survival and overall survival were markedly increased in both immunotherapy plus chemotherapy and immunotherapy monotherapy in comparison to chemotherapy alone. Conclusion: Immunotherapy alone and Immunotherapy plus Chemotherapy increased overall survival and progression free survival in comparison to chemotherapy alone in NSCLC.
Keywords: non-small cell lung cancer (NSCLC), chemotherapy, immunotherapy, overall survival, progression free survival.
Recommended Citation
Rush, Kristen, "Immunotherapy Versus Chemotherapy Efficacy in Promoting Survival of NSCLC" (2024). Summer Interdisciplinary Research Symposium. 226.
https://scholar.valpo.edu/sires/226
